^
Association details:
Biomarker:CLU-NRG1 fusion
Cancer:Ovarian Cancer
Drug:seribantumab (MM-121) (HER3 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Published date:
10/09/2020
Excerpt:
Administration of seribantumab (0.6-10 mg, BIW) to mice bearing LUAD-0061AS3 or OV-10-0050 (ovarian cancer PDX, CLU/NRG1 fusion) PDX tumors significantly reduced tumor growth, leading to approximately 60% and 100% regression in tumor size, respectively.